ÂÜÀòÂÒÂ×

Jürg Pfister, PhD has over 35 years of drug discovery and preclinical development experience in both major pharmaceutical and biotechnology start-up companies. He was formerly a Senior Research Fellow for the nicotinic acetylcholine receptor program at Comentis. Prior to that, he was Vice President of Medicinal Chemistry at Aryx Therapeutics, where he was a co-inventor of two new molecular entities that entered human clinical trials, the anticoagulant tecarfarin and the gastric prokinetic agent naronapride. Before that, he was a Senior Research Scientist at Roche Bioscience, leading a team of medicinal chemists in the Urology Therapeutic Area. Prior to that, he was the Director of Medicinal Chemistry and later the Director of Chemical Process Development at CV Therapeutics, where he was a co-inventor of two clinical stage adenosine receptor ligands, tecadenoson and naxiphylline. Before that, he held several research positions at Syntex where he was instrumental to the discovery of several new molecular entities that reached human clinical trials, including the anti-asthma agent tixanox and the congestive heart failure agent lixazinone. He was also the inventor of the potent third-generation multidrug resistance modulator zosuquidar which was licensed to Eli Lilly.

Dr. Pfister received a PhD degree in Organic Chemistry from the Swiss Federal Institute of Technology (ETH) and pursued postdoctoral studies at Syntex Research. He is an inventor on 78 U.S. patents and patent applications.